FI3638243T3 - Menetelmiä myeloproliferatiivin neoplasma-assosioidun myelofibroosin ja anemian hoitamiseksi - Google Patents
Menetelmiä myeloproliferatiivin neoplasma-assosioidun myelofibroosin ja anemian hoitamiseksi Download PDFInfo
- Publication number
- FI3638243T3 FI3638243T3 FIEP18816685.4T FI18816685T FI3638243T3 FI 3638243 T3 FI3638243 T3 FI 3638243T3 FI 18816685 T FI18816685 T FI 18816685T FI 3638243 T3 FI3638243 T3 FI 3638243T3
- Authority
- FI
- Finland
- Prior art keywords
- inhibitor
- actriib signaling
- subject
- use according
- actriib
- Prior art date
Links
- 206010028537 myelofibrosis Diseases 0.000 title claims 7
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 title claims 4
- 208000007502 anemia Diseases 0.000 title claims 2
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 27
- 239000003112 inhibitor Substances 0.000 claims 26
- 230000011664 signaling Effects 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 210000003743 erythrocyte Anatomy 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 2
- 229960000215 ruxolitinib Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010059186 Early satiety Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010000059 abdominal discomfort Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 206010029410 night sweats Diseases 0.000 claims 1
- 230000036565 night sweats Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 208000003476 primary myelofibrosis Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762519725P | 2017-06-14 | 2017-06-14 | |
| US201862679210P | 2018-06-01 | 2018-06-01 | |
| PCT/US2018/037213 WO2018231905A1 (en) | 2017-06-14 | 2018-06-13 | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3638243T3 true FI3638243T3 (fi) | 2024-10-29 |
Family
ID=64660712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18816685.4T FI3638243T3 (fi) | 2017-06-14 | 2018-06-13 | Menetelmiä myeloproliferatiivin neoplasma-assosioidun myelofibroosin ja anemian hoitamiseksi |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200101134A1 (https=) |
| EP (2) | EP4454707A3 (https=) |
| JP (2) | JP7496686B2 (https=) |
| CN (1) | CN111050770A (https=) |
| DK (1) | DK3638243T3 (https=) |
| ES (1) | ES2991738T3 (https=) |
| FI (1) | FI3638243T3 (https=) |
| HR (1) | HRP20241477T1 (https=) |
| HU (1) | HUE068733T2 (https=) |
| LT (1) | LT3638243T (https=) |
| PL (1) | PL3638243T3 (https=) |
| PT (1) | PT3638243T (https=) |
| RS (1) | RS66093B1 (https=) |
| SI (1) | SI3638243T1 (https=) |
| SM (1) | SMT202400437T1 (https=) |
| WO (1) | WO2018231905A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| CN108350057A (zh) | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| MA45811A (fr) | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7663502B2 (ja) * | 2018-10-31 | 2025-04-16 | セルジーン コーポレイション | 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| US20230181690A1 (en) * | 2020-04-13 | 2023-06-15 | Celgene Corporation | Methods for treating anemia using an actriib ligand trap and fedratinib |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CA3177632A1 (en) * | 2020-05-15 | 2021-11-18 | Melih ACAR | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| WO2022271716A2 (en) * | 2021-06-21 | 2022-12-29 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii signaling inhibitors |
| KR20240051971A (ko) * | 2021-08-19 | 2024-04-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 ii형 신호전달 억제제를 이용한 방법 |
| WO2025137373A1 (en) * | 2023-12-19 | 2025-06-26 | Cellarity, Inc. | Disease detection systems and methods |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| AU2010282361B2 (en) | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| KR20140084211A (ko) | 2011-10-17 | 2014-07-04 | 악셀레론 파마 인코포레이티드 | 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물 |
| JP2017509647A (ja) | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| CN114699529A (zh) * | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| US20180125928A1 (en) * | 2015-05-13 | 2018-05-10 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| CN108348578B (zh) * | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| EP3380121B1 (en) * | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| MA45811A (fr) | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
-
2018
- 2018-06-13 PL PL18816685.4T patent/PL3638243T3/pl unknown
- 2018-06-13 DK DK18816685.4T patent/DK3638243T3/da active
- 2018-06-13 SI SI201831166T patent/SI3638243T1/sl unknown
- 2018-06-13 PT PT188166854T patent/PT3638243T/pt unknown
- 2018-06-13 WO PCT/US2018/037213 patent/WO2018231905A1/en not_active Ceased
- 2018-06-13 RS RS20241154A patent/RS66093B1/sr unknown
- 2018-06-13 FI FIEP18816685.4T patent/FI3638243T3/fi active
- 2018-06-13 EP EP24186606.0A patent/EP4454707A3/en active Pending
- 2018-06-13 JP JP2019569312A patent/JP7496686B2/ja active Active
- 2018-06-13 LT LTEPPCT/US2018/037213T patent/LT3638243T/lt unknown
- 2018-06-13 HR HRP20241477TT patent/HRP20241477T1/hr unknown
- 2018-06-13 HU HUE18816685A patent/HUE068733T2/hu unknown
- 2018-06-13 ES ES18816685T patent/ES2991738T3/es active Active
- 2018-06-13 EP EP18816685.4A patent/EP3638243B1/en active Active
- 2018-06-13 SM SM20240437T patent/SMT202400437T1/it unknown
- 2018-06-13 CN CN201880052595.1A patent/CN111050770A/zh active Pending
- 2018-06-13 US US16/621,866 patent/US20200101134A1/en not_active Abandoned
-
2024
- 2024-02-27 JP JP2024027645A patent/JP2024075579A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020524139A (ja) | 2020-08-13 |
| JP2024075579A (ja) | 2024-06-04 |
| RS66093B1 (sr) | 2024-11-29 |
| EP3638243B1 (en) | 2024-08-07 |
| WO2018231905A1 (en) | 2018-12-20 |
| EP3638243A1 (en) | 2020-04-22 |
| JP7496686B2 (ja) | 2024-06-07 |
| ES2991738T3 (es) | 2024-12-04 |
| EP4454707A3 (en) | 2024-12-25 |
| US20200101134A1 (en) | 2020-04-02 |
| SMT202400437T1 (it) | 2024-11-15 |
| PT3638243T (pt) | 2024-10-31 |
| HUE068733T2 (hu) | 2025-01-28 |
| EP4454707A2 (en) | 2024-10-30 |
| LT3638243T (lt) | 2024-11-11 |
| HRP20241477T1 (hr) | 2025-01-03 |
| SI3638243T1 (sl) | 2025-03-31 |
| PL3638243T3 (pl) | 2025-02-10 |
| DK3638243T3 (da) | 2024-10-28 |
| WO2018231905A8 (en) | 2020-01-30 |
| CN111050770A (zh) | 2020-04-21 |
| EP3638243A4 (en) | 2021-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3638243T3 (fi) | Menetelmiä myeloproliferatiivin neoplasma-assosioidun myelofibroosin ja anemian hoitamiseksi | |
| Vadhan‐Raj et al. | Clinical applications of palifermin: amelioration of oral mucositis and other potential indications | |
| HRP20230504T1 (hr) | Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma | |
| JP2020524139A5 (https=) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| CA2338005A1 (en) | Peptide antagonists of zonulin and methods for use of the same | |
| US10471142B2 (en) | Combination therapy using immunoglobulin and C1-Inhibitor | |
| RU2001116077A (ru) | Способ лечения церебральных ишемий, а также применение эритропоэтина или производных эритропоэтина для лечения церебральных ишемий | |
| RU2019106804A (ru) | Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4 | |
| EA030513B1 (ru) | Комбинированная фармацевтическая композиция и способ лечения и профилактики инфекционных заболеваний | |
| PH12022551651A1 (en) | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4Ã7 INTEGRIN ANTAGONISTS | |
| TW201922282A (zh) | Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN107913395A (zh) | 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途 | |
| US9801938B2 (en) | Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists | |
| MXPA04007311A (es) | Tratamiento de ms con suero de cabra. | |
| Gorson | Therapy for vasculitic neuropathies | |
| RU2020117362A (ru) | Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17) | |
| WO2017088177A1 (zh) | 贻贝粘蛋白产品及其预防和抑制神经炎症的应用 | |
| Huang et al. | Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study | |
| CN108992671A (zh) | 一种药物组合物及其制备治疗肝损伤的药物中的用途 | |
| Wimer et al. | Mitogen information summaries | |
| US20210386736A1 (en) | Combination therapy for treating cancer | |
| RU2473364C2 (ru) | Способ лечения клещевого энцефалита | |
| US20140100165A1 (en) | Prevention of kidney injury or disease | |
| Todd et al. | (369) Emergency department femoral nerve blocks for acute hip fracture pain: a randomized controlled trial |